HC Wainwright & Co. Reiterates Icecure Medical (ICCM) Buy Recommendation
Fintel reports that on September 6, 2023, HC Wainwright & Co. reiterated coverage of Icecure Medical (NASDAQ:ICCM) with a Buy recommendation.
Analyst Price Forecast Suggests 251.86% Upside
As of August 31, 2023, the average one-year price target for Icecure Medical is 4.01. The forecasts range from a low of 3.03 to a high of $4.97. The average price target represents an increase of 251.86% from its latest reported closing price of 1.14.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Icecure Medical is 7MM, an increase of 111.46%. The projected annual non-GAAP EPS is -0.43.
What is the Fund Sentiment?
There are 15 funds or institutions reporting positions in Icecure Medical. This is an increase of 3 owner(s) or 25.00% in the last quarter. Average portfolio weight of all funds dedicated to ICCM is 0.00%, an increase of 441.66%. Total shares owned by institutions decreased in the last three months by 26.57% to 208K shares.